# Paradoxical Elevation of Parathyroid Hormone Levels following Preoperative Native Vitamin D Supplementation in a Patient with Graves’ Disease Undergoing Total Thyroidectomy: A Case Report

**Authors:** Hiroyuki Yamashita, Hisakazu Shindo, Yusuke Mori, Daisuke Tatsushima, Takashi Fukuda, Seigo Tachibana, Hiroshi Takahashi, Yuji Nagayama, Shinya Sato

PMC · DOI: 10.70352/scrj.cr.25-0465 · 2025-10-30

## TL;DR

A patient with Graves' disease experienced unexpected high parathyroid hormone levels after vitamin D supplementation before thyroid surgery.

## Contribution

This is the first report of paradoxical PTH elevation following preoperative vitamin D supplementation in a Graves’ disease patient.

## Key findings

- Preoperative vitamin D supplementation led to increased PTH and bone formation markers.
- FGF23 levels remained unchanged despite elevated PTH and 1,25-dihydroxyvitamin D.
- The patient developed transient hypoparathyroidism after surgery.

## Abstract

Hypocalcemia is a common complication after total thyroidectomy, particularly in patients with Graves’ disease and high bone turnover. Preoperative vitamin D deficiency is a known risk factor for postoperative hypocalcemia; however, the effects of vitamin D supplementation remain controversial. This is the first study to document a paradoxical increase in parathyroid hormone (PTH) levels after preoperative vitamin D supplementation in a patient undergoing total thyroidectomy.

We report the case of a 68-year-old woman with Graves’ disease and coexisting thyroid cancer who received native vitamin D (2000 IU/day) for 4 weeks before surgery. This unexpectedly resulted in a marked increase in PTH levels and bone formation markers, suggesting the worsening of secondary hyperparathyroidism. Interestingly, fibroblast growth factor 23 levels remained unchanged despite an increase in PTH and 1,25-dihydroxyvitamin D levels. Postoperatively, she developed transient hypoparathyroidism.

Native vitamin D supplementation may, paradoxically, worsen secondary hyperparathyroidism in some patients, highlighting the need for careful preoperative metabolic assessment and individualized management strategies.

## Linked entities

- **Chemicals:** 1,25-dihydroxyvitamin D (PubChem CID 5280453)
- **Diseases:** Graves’ disease (MONDO:0005364), thyroid cancer (MONDO:0002108), hypocalcemia (MONDO:0018543), secondary hyperparathyroidism (MONDO:0006964), hypoparathyroidism (MONDO:0001220)

## Full-text entities

- **Genes:** PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}
- **Diseases:** Hypocalcemia (MESH:D006996), secondary hyperparathyroidism (MESH:D006962), Graves' Disease (MESH:D006111), hypoparathyroidism (MESH:D007011), thyroid cancer (MESH:D013964), vitamin D (MESH:D014808)
- **Chemicals:** 1,25-dihydroxyvitamin D (MESH:C097949), Vitamin D (MESH:D014807)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12582898/full.md

---
Source: https://tomesphere.com/paper/PMC12582898